TW200633728A - Stable non-dihydrate azithromycin oral suspensions - Google Patents

Stable non-dihydrate azithromycin oral suspensions

Info

Publication number
TW200633728A
TW200633728A TW094145377A TW94145377A TW200633728A TW 200633728 A TW200633728 A TW 200633728A TW 094145377 A TW094145377 A TW 094145377A TW 94145377 A TW94145377 A TW 94145377A TW 200633728 A TW200633728 A TW 200633728A
Authority
TW
Taiwan
Prior art keywords
azithromycin
stable non
oral suspensions
dihydrate azithromycin
dihydrate
Prior art date
Application number
TW094145377A
Other languages
English (en)
Inventor
Barbara Alice Johnson
Brendan John Murphy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200633728A publication Critical patent/TW200633728A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094145377A 2004-12-21 2005-12-20 Stable non-dihydrate azithromycin oral suspensions TW200633728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63821804P 2004-12-21 2004-12-21

Publications (1)

Publication Number Publication Date
TW200633728A true TW200633728A (en) 2006-10-01

Family

ID=36602128

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094145377A TW200633728A (en) 2004-12-21 2005-12-20 Stable non-dihydrate azithromycin oral suspensions

Country Status (7)

Country Link
US (1) US20100048498A1 (zh)
EP (1) EP1830860A2 (zh)
JP (1) JP2008524318A (zh)
AR (1) AR052060A1 (zh)
CA (1) CA2591744A1 (zh)
TW (1) TW200633728A (zh)
WO (1) WO2006067577A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278309B2 (en) 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
WO2010125212A1 (es) * 2009-04-27 2010-11-04 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Suspensión oral de lisinato de ibuprofeno
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20160079781A (ko) * 2013-11-08 2016-07-06 액티버스 파마 컴퍼니 리미티드 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
JP6711875B2 (ja) * 2018-08-29 2020-06-17 日本食品化工株式会社 マクロライド化合物の苦味抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
CN1273142C (zh) * 1998-11-30 2006-09-06 特瓦制药工业有限公司 阿齐霉素的乙醇化物,制备方法以及医药组合物
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60232005D1 (de) * 2001-10-18 2009-05-28 Teva Pharma Stabilisierte azithromycin-zusammensetzungen
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
GB0214277D0 (en) * 2002-06-20 2002-07-31 Biochemie Gmbh Organic compounds
GB0224197D0 (en) * 2002-10-17 2002-11-27 Biochemie Gmbh Organic compounds
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions

Also Published As

Publication number Publication date
AR052060A1 (es) 2007-02-28
WO2006067577A3 (en) 2006-12-28
EP1830860A2 (en) 2007-09-12
CA2591744A1 (en) 2006-06-29
JP2008524318A (ja) 2008-07-10
US20100048498A1 (en) 2010-02-25
WO2006067577A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
TW200700086A (en) Injectable non-aqueous suspension
EP1740156B8 (de) Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
HK1120016A1 (en) Method for producing fullerene suspension
MX2008016039A (es) Preparacion de glucano.
WO2007117503A3 (en) Preparing nanoparticles and carbon nanotubes
TW200717389A (en) Luminance adjustment
TW200714549A (en) Method and apparatus for the production of ultrafine silica particles from solid silica powder and related coating compositions
WO2007025861A3 (de) Modifizierte kohlenstoff-nanopartikel, verfahren zu deren herstellung und deren verwendung
GB0615922D0 (en) Method for producing particles,particles,and sintered body
TW200801161A (en) Gas-phase infiltration of phosphors into the pore system of inverse opals
SG150518A1 (en) Macrolides and methods for producing same
WO2008008917A3 (en) Hydroxyapatite particles
TW200633728A (en) Stable non-dihydrate azithromycin oral suspensions
MX2007004137A (es) Panel estructural ligero y metodo para fabricarlo.
UA87568C2 (ru) Способ и его применение для борьбы с паразитами, паразитицидный порошок
UA91733C2 (ru) Способ получения кристаллической формы орлистата
ZA200903637B (en) Method for producing stable, high-purity molded bodies from pyrogenic metal oxides without the addition of binders
NO20060611L (no) Stabile ikke-dihydratazitromycin oralsuspensjoner
TW200719381A (en) Electrode system for a lamp
EP1930310A4 (en) PROCESS FOR PRODUCING 3,3,3-TRIFLUOROPROPIONALDEHYDE
WO2007008588A3 (en) Omeprazole form b
TW200505399A (en) Hydroxylapatite powder, porous body and method for preparing thereof
IL184942A0 (en) Azithromycin powder for oral suspension compositions
ZA200801104B (en) Method for the production of 2,4,6-trimercapto-1,3,5-triazine
MX2007007045A (es) Estabilizador uv para pmma.